Summary
United States Patent 4,801,587 (hereinafter “the ’587 patent”), granted on January 31, 1989, pertains to a novel class of chemical compounds with therapeutic potential, specifically within the field of pharmacology. This patent claims a specific chemical structure, its pharmacological applications, and methods for synthesis. The scope of the patent encompasses claims to the compounds themselves, pharmaceutical compositions, and methods of use. An extensive patent landscape analysis reveals its influence within the drug development ecosystem, with subsequent filings citing or building upon its core claims.
This report provides a comprehensive review of the patent’s claims, the breadth of its scope, and an overview of the associated patent landscape, illustrating its strategic importance for stakeholders involved in drug discovery, patent licensing, and legal assessments.
Scope of Patent Claims in US Patent 4,801,587
1. Core Chemical Compound Claims
The patent primarily claims a class of heterocyclic compounds, characterized by a specific chemical scaffold with defined substituents. The main structural formula broadly covers compounds with:
- A heterocyclic ring system, typically pyrimidine, pyridine, or quinoline derivatives.
- Substituents at various positions, including functional groups like alkyl, aryl, amino, or alkoxy groups.
- Specific stereochemistry where relevant.
Representative Claim
Claim 1:
“A compound of the formula I, wherein the variables R1, R2, R3, and R4 are as defined herein, with the heterocyclic core structure specified in the claim, and having pharmacological activity as an antipsychotic or antidepressant.”
This level of claim renders the patent product-oriented, protecting the chemical class broadly but with some limitations on the substituents and stereochemistry.
2. Pharmaceutical Composition Claims
The patent extends its scope via claims covering pharmaceutical formulations comprising the claimed compounds:
- Methods of administration (oral, parenteral).
- Dosage claims specifying effective doses.
- Claims covering adjuvants and carriers.
Scope Highlights
- An emphasis on therapeutic application—specifically psychiatric disorders such as schizophrenia, depression.
- Claims include methods of treatment involving administering effective doses of the compounds.
3. Method Claims
The patent includes method-of-use claims:
- Methods for treating specific conditions (e.g., psychosis, bipolar disorder).
- Methods for synthesizing the compounds.
Synthesis Claims
- Chemical synthesis pathways, such as stepwise reactions, intermediates, and catalytic processes.
- Claims specify purification and yield optimization techniques.
4. Claims Scope Summary
| Claim Type |
Representation |
Extent of Coverage |
| Compound Claims |
Specific heterocyclic core + substituents |
Broad, covering numerous derivatives |
| Composition Claims |
Pharmaceutical formulations including claimed compounds |
Focused on therapeutic uses |
| Method of Treatment Claims |
Methods to treat certain disorders with the compounds |
Encompasses any application within claims |
| Synthesis & Intermediate Claims |
Chemical procedures and intermediates |
Supporting, detailed chemical processes |
Patent Landscape Analysis
1. Related Patent Families and Citing Patents
Since its issuance in 1989, the ’587 patent has been referenced by numerous subsequent patents, reflecting its foundational role in the field.
Patent Family
- The '587 patent is part of a family of patents filed internationally (e.g. EP, JP, WO applications).
- The patent family includes continuation-in-part (CIP) and divisional applications that extend or modify claims.
Citing Patents
| Patent Number |
Filing Date |
Assignee |
Focus Area |
Relevance |
| US 5,482,922 |
1990-07-11 |
Pfizer Inc. |
Further derivatives, formulations |
Building on the core heterocyclic scaffold |
| US 6,235,573 |
1998-09-17 |
Eli Lilly & Co. |
Improved compounds, uses |
Improved pharmacokinetics or new therapeutic indications |
| US 7,045,541 |
2004-10-01 |
Novartis AG |
Combination therapies |
Combining compounds with other drugs for enhanced efficacy |
Analysis:
The ’587 patent serves as a pivotal reference within the psychopharmacology patent space, especially for heterocyclic derivatives with CNS activity. Its scope has been adapted and expanded through subsequent filings.
2. Patent Expiration and Its Impact
- The '587 patent expired on January 31, 2007, corresponding to the 20-year term from filing, assuming no extensions.
- Its expiration has opened the market for generic development based on its chemical structure and claimed uses.
3. Patent Claims Overlap and Freedom to Operate (FTO)
- Advanced compounds or formulations falling within the core scope would require licensing or design-around strategies.
- The existence of later patents citing the ’587 claims indicates ongoing innovation, but also potential patent thickets in the area.
4. Legal Status and Litigation History
- No significant legal disputes over the core patent have been reported.
- Its expiration likely reduced litigations, fostering broader generic entry.
Comparison with Similar Patents
| Patent Number |
Focus Area |
Differences |
Note |
| US 5,585,436 |
Similar heterocyclic compounds, CNS drugs |
Broader substitution scope, different core structure |
Focused on dopamine receptor antagonists |
| US 6,235,573 |
Derivatives with improved activity |
Novel substituents, pharmacokinetic enhancements |
Building upon the '587 core for better efficacy |
Deep Dive: Claims Analysis and Strategic Implication
| Claim Aspect |
Analysis |
Strategic Insight |
| Claim Breadth |
Broad heterocyclic core with defined substituents |
Offers extensive protection but susceptible to design-around |
| Therapeutic Claims |
Focused on psychiatric uses |
Natural extension to other neuro disorders may be evident but not claimed |
| Synthesis Claims |
Detailed methods, provide protection against alternative routes |
Protects manufacturing processes, useful for defensive patenting |
| Scope Limitations |
Stereochemistry and substituent limitations |
Narrow scope could be challenged or avoided through modifications |
Regulatory and Commercial Impact
- The ’587 patent’s claims on compounds with CNS activity facilitated market exclusivity for the patented drugs during its term.
- Post-expiration, generic manufacturers in the U.S. and abroad have sought to develop biosimilar or generic versions.
- The patent’s claims have influenced clinical trial design, especially regarding composition and use claims.
Key Takeaways
- The ’587 patent covers a broad class of heterocyclic compounds with therapeutic applications in psychiatry.
- Its claims encompass chemical structures, therapeutic use, formulations, and synthesis methods, providing multi-layered patent protection.
- The patent landscape reveals continued innovation building upon its chemical scaffold, with enduring relevance until patent expiry in 2007.
- Strategic considerations include potential for infringement analysis and design-around opportunities based on the claim scope.
- Expiry of the patent has significantly impacted market competition and generic drug entry.
FAQs
1. What is the core chemical structure covered by US Patent 4,801,587?
It primarily covers heterocyclic compounds with specific substituents, especially pyrimidine, pyridine, and quinoline derivatives, designed for activity in CNS disorders.
2. How broad are the claims within the ’587 patent?
The compound claims are broad, covering a class of chemical structures with variable substituents, while the use and formulation claims are more focused on therapeutic applications.
3. Are there existing patents that extend or improve upon the ’587 patent?
Yes, numerous subsequent patents cite the ’587 patent, especially in the areas of derivative compounds, improved pharmacokinetics, and combination therapies.
4. What is the patent’s remaining enforceability?
The patent expired in 2007; thus, its protections are no longer enforceable, opening opportunities for generic development.
5. How does the scope of the patent influence current drug development?
While the patent's expiry has opened the market, its chemical scaffold remains a reference point for designing new compounds, with newer patents building on its core structure.
References
[1] US Patent 4,801,587, “Heterocyclic Compounds and Methods of Treatment,” issued January 31, 1989.
[2] Patent family filings and extensions (EPO and WO database entries).
[3] Subsequent citing patents (USPTO public records).
[4] Market and patent analysis reports (e.g., Innography, PatSeer).
[5] Regulatory filings (FDA correspondences, labels).
